Initiation of coverage HUMANIGEN BUY – TP USD30 | Putting Lenz in the eye of cytokine storm
Humanigen - a biotech company that is leveraging its deep understanding in targeting GM-CSF, a key factor in inflammation, to develop effective treatment against diseases associated with cytokine storm (CS). While its lead asset, lenzilumab (lenz), has potential in other CS-like diseases, the recent impressive stock run (+515% since March 19, 2020) was spun by COVID-19 programme. With phase III expected to readout in Q4 2020, we see COVID-19 as a near-term commercial opportunity for the company. Over the longer-term, we believe that the stock could be supported by clinical catalysts in prevention of CAR-T-associated CRS and aGvHD.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.